Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Differential Declines in Striatal Nicotinic Receptor Subtype Function after Nigrostriatal Damage in Mice

Maryka Quik, Jocelyn D. Sum, Paul Whiteaker, Sarah E. McCallum, Michael J. Marks, John Musachio, J. Michael Mcintosh, Allan C. Collins and Sharon R. Grady
Molecular Pharmacology May 2003, 63 (5) 1169-1179; DOI: https://doi.org/10.1124/mol.63.5.1169
Maryka Quik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jocelyn D. Sum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Whiteaker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah E. McCallum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Marks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Musachio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael Mcintosh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan C. Collins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon R. Grady
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Nigrostriatal damage leads to a reduction in striatal nicotinic acetylcholine receptors (nAChRs) in rodents, monkeys, and patients with Parkinson's disease. The present studies were undertaken to investigate whether these nAChR declines are associated with alterations in striatal nAChR function and, if so, to identify the receptor subtypes involved. To induce nigrostriatal damage, mice were injected with the selective dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We measured [125I]3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester (RTI-121, dopamine transporter),125I-α-conotoxin MII (putative α6-containing sites in the central nervous system), 125I-epibatidine (multiple sites), 5-[125I]iodo-3-[2(S)-azetidinylmethoxy]pyridine-2HCl ([125I]A85380; β2-containing sites), and125I-α-bungarotoxin (α7-containing sites) binding in brains from control and MPTP-treated mice, as well as nAChR function by [3H]dopamine release, [3H]GABA release, and [86Rb+] efflux. After MPTP treatment, declines were observed in striatal dopamine transporter levels, both binding and functional measures of striatal α-conotoxin MII-sensitive nAChRs, and selected measures of striatal α-conotoxin MII-resistant nAChRs. In contrast, 125I-α-bungarotoxin binding sites were not altered after nigrostriatal damage. The changes in striatal nAChRs were selective, with no declines in cortex, thalamus, or septum. Those striatal binding and functional measures of nAChRs that decreased with MPTP treatment correlated with dopamine transporter declines, an observation suggesting that the binding and functional changes in nAChRs are limited to dopaminergic terminals. The present results are the first to demonstrate differential alterations in nAChR subtype function after nigrostriatal damage, with a close correspondence between changes in receptor binding sites and function. These data suggest that the declines in nAChR sites observed in Parkinson's disease brains may be of functional significance.

Footnotes

  • This work was supported by the California Tobacco Related Disease Research Program 11RT-0216 (to M.Q.), National Institute of Neurological Disorders and Stroke grant NS42091 (to M.Q.), National Institute on Drug Abuse grants DA12242 (to M.J.M.), DA00197 (to A.C.C.), and DA03194 (to A.C.C.), National Institute of Mental Health grant MH53631 (to J.M.M.), National Institute of General Medical Sciences grant GM48677 (to J.M.M.), and Colorado Tobacco Research Program CTRP 2R-033 (to A.C.C.).

  • Abbreviations:
    nAChR
    nicotinic acetylcholine receptor
    [125I]A85380
    5-[125I]iodo-3-[2(S)-azetidinylmethoxy]pyridine-2HCl
    MPTP
    1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
    RTI-121
    3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester
    *
    nicotinic receptors containing the indicated α and/or β subunit and possibly additional undefined subunits
    dopa
    3,4-dihydroxyphenylalanine
    BSA
    bovine serum albumin
    • Received January 8, 2003.
    • Accepted February 12, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 63 (5)
Molecular Pharmacology
Vol. 63, Issue 5
1 May 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Differential Declines in Striatal Nicotinic Receptor Subtype Function after Nigrostriatal Damage in Mice
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Differential Declines in Striatal Nicotinic Receptor Subtype Function after Nigrostriatal Damage in Mice

Maryka Quik, Jocelyn D. Sum, Paul Whiteaker, Sarah E. McCallum, Michael J. Marks, John Musachio, J. Michael Mcintosh, Allan C. Collins and Sharon R. Grady
Molecular Pharmacology May 1, 2003, 63 (5) 1169-1179; DOI: https://doi.org/10.1124/mol.63.5.1169

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Differential Declines in Striatal Nicotinic Receptor Subtype Function after Nigrostriatal Damage in Mice

Maryka Quik, Jocelyn D. Sum, Paul Whiteaker, Sarah E. McCallum, Michael J. Marks, John Musachio, J. Michael Mcintosh, Allan C. Collins and Sharon R. Grady
Molecular Pharmacology May 1, 2003, 63 (5) 1169-1179; DOI: https://doi.org/10.1124/mol.63.5.1169
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-aromatase activity of exemestane phase II metabolites
  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics